How Will the Prevnar Market Grow? Key Trends and Opportunities for 2025 and Beyond
Enjoy a flat 15% OFF on all 2025 Global Market Reports until March 31st! Use code FY25SAVE to save big—don’t miss out!
How has the prevnar market grown in recent years?
The Prevnar marketplace has seen an XX (HCAGR) increase in its size in the latest years. It’s projected to expand from $XX million in 2024 to $XX million in 2025, demonstrating a compound annual growth rate (CAGR) of XX%. Factors contributing to the positive growth throughout the historic period include the extension of pediatric vaccination schedules, high prevalence of pneumococcal diseases, collaborations between private and public healthcare sectors, global initiatives including Gavi, and better access to healthcare.
How is the prevnar market size expected to evolve during the forecast period?
The market size for Prevnar is projected to experience an XX (FCAGR) increase in the coming few years, reaching $XX million by 2029 with a XX% compound annual growth rate (CAGR). The predicted growth over the forecast period is due to a demand for adult immunization, the emergence of antibiotic-resistant strains, escalating urbanization, epidemiological changes, and the increase in regular adult vaccination. Key trends identified for the forecast period include improvements in conjugate vaccine technology, the incorporation into the universal immunization schedule, application of predictive analytics, telehealth use for vaccine awareness, and the creation of alternatives to needle-based vaccines.
Get your prevnar market report here!
https://www.thebusinessresearchcompany.com/report/prevnar-global-market-report
Which key drivers are propelling the prevnar market’s growth?
The growth of the prevnar market is anticipated to be driven by the escalating occurrence of pneumococcal diseases. These infections, which include conditions ranging from the mild, such as sinusitis and otitis media, to the severe, like pneumonia, meningitis, and sepsis, are caused by streptococcus pneumoniae. Several contributing factors are causing a rise in these diseases, such as growing antibiotic resistance, an aging populace with weaker immune responses, and insufficient vaccination coverage. Prevnar, a pneumococcal vaccine, is used to guard against infections from streptococcus pneumoniae, including pneumonia, meningitis, and bloodstream infections, by promoting an immune response to multiple pneumococcal strains. A report from the Statens Serum Institut, a Denmark-based medical laboratory, from May 2024 showed that cases of invasive pneumococcal disease rose from 553 in 2022 to 622 in 2023. Consequently, the growing instances of pneumococcal diseases are boosting the Prevnar market.
What are the market segments in the prevnar industry?
The prevnar market covered in this report is segmented –
1) By Formulation: Prevnar 13, Prevnar 20
2) By Indications: Pneumonia, Meningitis, Sepsis, Other Indications
3) By Distribution Channel: Distribution Partner Companies, Non-governmental Organizations, Government Authorities
4) By End Users: Pediatric, Geriatric, Adult
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20188&type=smp
Which leading companies are shaping the growth of the prevnar market?
Major companies operating in the prevnar market include Pfizer Inc.
What key trends are currently impacting the prevnar market’s development?
One of the main trends in the Prevnar market is the emphasis on securing regulatory approvals to sustain their market dominance. Such approvals are essential to guarantee the safety, effectiveness, and quality of Prevnar, thereby promoting its comprehensive acceptance and widespread use. As an example, Pfizer Inc., an American pharmaceutical company, received approval from the FDA for PREVNAR 20 (20-valent Pneumococcal Conjugate Vaccine) in April 2023. This approval relates to the prevention of invasive pneumococcal disease (IPD) provoked by the 20 Streptococcus pneumoniae (pneumococcal) serotypes covered by the vaccine, for infants and children from 6 weeks to 17 years of age. It also includes the prevention of otitis media for infants between six weeks and 5 years of age, caused by the initial seven serotype conjugates contained in PREVNAR.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20188
Which geographic areas are influencing the growth of the prevnar market?
North America was the largest region in the prevnar market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prevnar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Pneumococcal Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report
Travel Vaccines Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/travel-vaccines-global-market-report
Vaccine Contract Manufacturing Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
